home

Amazon Alexa Adds Health Advice With Boston Children’s Hospital App

Healthxconomy2016-04-13 16:39 Read   63

Owners of Amazon’s voice-controlled, Internet-connected Echo speaker can ask it to play that catchy new song or find out whether they need to wear a rain coat today.

Valeant wins new 10-K deadline from creditors, but gives up dealmaking freedom in return

EVENTSfiercepharma2016-04-13 14:56 Read   66

Valeant wins new 10-K deadline from creditors, but gives up dealmaking freedom in return

Bill to rein in drug costs spurs controversy

Commentsbostonglobe2016-04-13 14:48 Read   71

Leslie Wood representing PhRMA, Pharmaceutical Research and Manufacturers of America, testified Monday before the state Legislature’s Joint Committee on Health Care Financing at a public hearing on prescription drug prices.

New myeloma meds work better than the old, but they're far too expensive: Report

Commentsfiercepharma2016-04-13 14:32 Read   86

The Institute for Clinical and Economic Review's new multiple myeloma drug assessment stirred up criticism even before it went public. Now, the not-for-profit group has unveiled its draft report, grading a half-dozen treatment regimens for cost-effectiveness.

Incoming Bayer CEO looks to deals to beef up $1.7B animal health unit

EVENTSfiercepharma2016-04-13 14:13 Read   77

Bayer's incoming CEO Werner Baumann knows a thing or two about dealmaking, and he's ready to put his M&A smarts to good use. Baumann wants to build up the company's animal health unit through targeted acquisitions and partnerships once he takes the reins next month.

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

EVENTSregeneron2016-04-13 13:55 Read   122

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development.

Forbion Closes Third Life Sciences Fund, FCF III, Raising over USD200M

EVENTSb3cnewswire2016-04-13 13:28 Read   46

Investment focus on European, US & Canadian private companies developing novel drugs, medical devices and diagnostics

Arena’s cannabinoid pain drug passes early-stage test

R&Dyahoo2016-04-13 13:04 Read   88

Arena Pharmaceuticals, Inc. (ARNA) today announced favorable results from its Phase 1b multiple-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor with potential utility in the treatment of pain.

LifeSci Advisors aim for model behavior after 'serious mistake'

EVENTSfiercebiotech2016-04-13 12:50 Read   56

Picture this: You’re a life science professional, attending an after-party event at the JP Morgan Healthcare Conference in San Francisco run by investor relations firm LifeSci Advisors. You’d expect to be in the company of some serious professionals, but instead you’re surrounded by 70 svelte models in a situation that would not have been out of place on Mad Men.

FDA advisors vote against Clovis' rociletinib

Regulatorpharmatimes2016-04-13 11:09 Read   103

It looks likely that Clovis Oncology’s non-small cell lung cancer drug rociletinib will hit a major setback in its quest for approval after failing to win the support of US Food and Drug Administration advisors.

First Zika vaccine may start clinical trials in September; Congress yet to fund research

R&Dhealthcarefinancenews2016-04-13 10:56 Read   96

Without funding, feds may have to redirect money currently dedicated for research into malaria, tuberculosis and a universal flu vaccine.

Does Biogen selling its hemophilia franchise make sense? Leerink's top analyst says yes

Commentsfiercepharma2016-04-13 10:06 Read   140

As rumors abound that Biogen ($BIIB) is looking to get rid of its $800 million hemophilia assets, some analysts are saying hey, you might as well--and you could see $6 billion for your troubles.